15q Clinical Research Network COVID-19 Vaccine Position Statement

January 14, 2021

The following statement is offered to the Angelman Syndrome and Dup15q Community from the 15q Clinical Research Network. 

The CDC has recently posted information regarding the COVID vaccine: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html

An FDA Advisory panel voted to recommend the authorization of the Pfizer COVID vaccine for emergency use in individuals 16 years and older and the Moderna COVID vaccine for individuals 18 years and older. We hope that these will be the first of many vaccines that will become available over the coming months. The key to getting us all back into schools and therapies and life is for those around our individuals with AS or Dup15q to receive the vaccination, as well as those with AS/Dup15q. While it may not yet be approved for all ages, when it is, the AS and Dup15q Community stands behind universal vaccination, especially for individuals with AS or Dup15q.  For those patients who are too young to be vaccinated, we strongly urge you to have all primary caregivers get vaccinated to protect them until a vaccine is available in their age range.

Another day without vaccination is another day of lost therapies, opportunities, and life. Now is not the time to ponder. We encourage all to take the vaccine as soon as it is offered, unless contraindicated for you or your loved ones.

Ours clinicians and experts at the 15q Clinical Research Network have prepared the following information and FAQs to specifically address concerns regarding the COVID-19 vaccine currently being administered in the US. 

Visit the 15q CRN Network website for more information and FAQ’s at the link below.

COVID-19 Vaccine Position Statement & FAQ’s from December 2020 – 15q Clinical Research Network

If you have any questions or concerns, please contact our 15q CRN Coordin